ArticleClinical Medicine Insights. Oncology2026
Efficacy of Pembrolizumab as a Second- or Third-Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Multicenter Retrospective Study in Vietnamese Patients.
Phuong Thi Bich Nguyen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.